Ascendis Pharma: TransCon PTH data show normalized bone measures over 5 years in hypoparathyroidism

New long-term pooled data for Ascendis Pharma's TransCon PTH in chronic hypoparathyroidism, to be presented at ASBMR 2026, are set to show treated patients reached normalized bone mass and bone microarchitecture over five years.